 Connection
Alan Gamis to Neoplasm, Residual
This is a "connection" page, showing publications Alan Gamis has written about Neoplasm, Residual.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.465 |
|
|
|
-
Taub JW, Berman JN, Hitzler JK, Sorrell AD, Lacayo NJ, Mast K, Head D, Raimondi S, Hirsch B, Ge Y, Gerbing RB, Wang YC, Alonzo TA, Campana D, Coustan-Smith E, Mathew P, Gamis AS. Improved outcomes for myeloid leukemia of Down syndrome: a report from the Children's Oncology Group AAML0431 trial. Blood. 2017 06 22; 129(25):3304-3313.
Score: 0.148
-
Loken MR, Alonzo TA, Pardo L, Gerbing RB, Raimondi SC, Hirsch BA, Ho PA, Franklin J, Cooper TM, Gamis AS, Meshinchi S. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood. 2012 Aug 23; 120(8):1581-8.
Score: 0.106
-
Hitzler J, Alonzo T, Gerbing R, Beckman A, Hirsch B, Raimondi S, Chisholm K, Viola S, Brodersen L, Loken M, Tong S, Druley T, O'Brien M, Hijiya N, Heerema-McKenney A, Wang YC, Schore R, Taub J, Gamis A, Kolb EA, Berman JN. High-dose AraC is essential for the treatment of ML-DS independent of postinduction MRD: results of the COG AAML1531 trial. Blood. 2021 12 09; 138(23):2337-2346.
Score: 0.051
-
Elgarten CW, Wood AC, Li Y, Alonzo TA, Brodersen LE, Gerbing RB, Getz KD, Huang YV, Loken M, Meshinchi S, Pollard JA, Sung L, Woods WG, Kolb EA, Gamis AS, Aplenc R. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 12; 68(12):e29281.
Score: 0.051
-
Brodersen LE, Gerbing RB, Pardo ML, Alonzo TA, Paine D, Fritschle W, Hsu FC, Pollard JA, Aplenc R, Kahwash SB, Hirsch B, Ramondi S, Wells D, Kolb EA, Gamis AS, Meshinchi S, Loken MR. Morphologic remission status is limited compared to ?N flow cytometry: a Children's Oncology Group AAML0531 report. Blood Adv. 2020 10 27; 4(20):5050-5061.
Score: 0.047
-
Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S. NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report. Blood. 2014 Oct 09; 124(15):2400-7.
Score: 0.031
-
Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB. High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Leuk Lymphoma. 2014 Dec; 55(12):2817-21.
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|